Optimizing Outcomes in Familial Hypercholesterolemia: Diagnosis, Treatment, and Management - a podcast by ReachMD

CME credits: 0.50

Valid until: 30-06-2022

Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-familial-hypercholesterolemia-diagnosis-treatment-and-management/12554/

According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD